Association between hospital volume, therapy types, and overall survival in stage III and IV cutaneous malignant melanoma

Sri Harsha Tella, Anuhya Kommalapati, Apar Kishor Ganti, Alissa S. Marr

Research output: Contribution to journalArticle

Abstract

Background: The advent of targeted therapies and immunomodulatory agents has revolutionized the management of advanced cutaneous malignant melanoma (MMel) by prolonging overall survival. This study evaluated the therapeutic and survival disparities among patients with advanced MMel based on hospital volume using the National Cancer Database (NCDB). Methods: A retrospective analysis using regression models and Kaplan-Meier estimates was performed from the data obtained from the NCDB on patients with MMel diagnosed in 2004 through 2015. Results: A total of 40,676 patients with MMel were treated at 1,260 facilities. Multivariable analysis showed that facility volume was an independent predictor of overall survival (P,.0001). Compared with patients treated at high-volume facilities (tertile 3 [T3]), those with stage III disease (n527,528) treated at intermediate-and low-volume facilities (T2 and T1, respectively) had a significantly higher risk of death (T2 hazard ratio [HR], 1.15; 95% CI, 1.09-1.20; T1 HR, 1.23; 95% CI, 1.17-1.29). Compared with patients treated at T3 facilities, those with stage IV disease (n513,148) treated at lower-tertile facilities had a significantly higher risk of death (T2 HR, 1.16; 95% CI, 1.10-1.21; T1 HR, 1.29; 95% CI, 1.23-1.36). Further, patients with stage IV disease treated at T3 facilities (vs T1 facilities) were more likely to receive chemotherapy (38% vs 28%) and immunotherapy (23% vs 10%) (P,.0001). Conclusions: Patients with advanced-stage MMel treated at high-volume facilities had significantly improved survival and were more likely to receive chemotherapy and immunotherapy.

Original languageEnglish (US)
Pages (from-to)1334-1342
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Survival
Melanoma
Immunotherapy
Therapeutics
Databases
Drug Therapy
Immunomodulation
Kaplan-Meier Estimate
Cutaneous Malignant Melanoma
Neoplasms
Regression Analysis

ASJC Scopus subject areas

  • Oncology

Cite this

@article{dae52d20698a4e86b65f232e96fb448e,
title = "Association between hospital volume, therapy types, and overall survival in stage III and IV cutaneous malignant melanoma",
abstract = "Background: The advent of targeted therapies and immunomodulatory agents has revolutionized the management of advanced cutaneous malignant melanoma (MMel) by prolonging overall survival. This study evaluated the therapeutic and survival disparities among patients with advanced MMel based on hospital volume using the National Cancer Database (NCDB). Methods: A retrospective analysis using regression models and Kaplan-Meier estimates was performed from the data obtained from the NCDB on patients with MMel diagnosed in 2004 through 2015. Results: A total of 40,676 patients with MMel were treated at 1,260 facilities. Multivariable analysis showed that facility volume was an independent predictor of overall survival (P,.0001). Compared with patients treated at high-volume facilities (tertile 3 [T3]), those with stage III disease (n527,528) treated at intermediate-and low-volume facilities (T2 and T1, respectively) had a significantly higher risk of death (T2 hazard ratio [HR], 1.15; 95{\%} CI, 1.09-1.20; T1 HR, 1.23; 95{\%} CI, 1.17-1.29). Compared with patients treated at T3 facilities, those with stage IV disease (n513,148) treated at lower-tertile facilities had a significantly higher risk of death (T2 HR, 1.16; 95{\%} CI, 1.10-1.21; T1 HR, 1.29; 95{\%} CI, 1.23-1.36). Further, patients with stage IV disease treated at T3 facilities (vs T1 facilities) were more likely to receive chemotherapy (38{\%} vs 28{\%}) and immunotherapy (23{\%} vs 10{\%}) (P,.0001). Conclusions: Patients with advanced-stage MMel treated at high-volume facilities had significantly improved survival and were more likely to receive chemotherapy and immunotherapy.",
author = "Tella, {Sri Harsha} and Anuhya Kommalapati and Ganti, {Apar Kishor} and Marr, {Alissa S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.6004/jnccn.2019.7320",
language = "English (US)",
volume = "17",
pages = "1334--1342",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "11",

}

TY - JOUR

T1 - Association between hospital volume, therapy types, and overall survival in stage III and IV cutaneous malignant melanoma

AU - Tella, Sri Harsha

AU - Kommalapati, Anuhya

AU - Ganti, Apar Kishor

AU - Marr, Alissa S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The advent of targeted therapies and immunomodulatory agents has revolutionized the management of advanced cutaneous malignant melanoma (MMel) by prolonging overall survival. This study evaluated the therapeutic and survival disparities among patients with advanced MMel based on hospital volume using the National Cancer Database (NCDB). Methods: A retrospective analysis using regression models and Kaplan-Meier estimates was performed from the data obtained from the NCDB on patients with MMel diagnosed in 2004 through 2015. Results: A total of 40,676 patients with MMel were treated at 1,260 facilities. Multivariable analysis showed that facility volume was an independent predictor of overall survival (P,.0001). Compared with patients treated at high-volume facilities (tertile 3 [T3]), those with stage III disease (n527,528) treated at intermediate-and low-volume facilities (T2 and T1, respectively) had a significantly higher risk of death (T2 hazard ratio [HR], 1.15; 95% CI, 1.09-1.20; T1 HR, 1.23; 95% CI, 1.17-1.29). Compared with patients treated at T3 facilities, those with stage IV disease (n513,148) treated at lower-tertile facilities had a significantly higher risk of death (T2 HR, 1.16; 95% CI, 1.10-1.21; T1 HR, 1.29; 95% CI, 1.23-1.36). Further, patients with stage IV disease treated at T3 facilities (vs T1 facilities) were more likely to receive chemotherapy (38% vs 28%) and immunotherapy (23% vs 10%) (P,.0001). Conclusions: Patients with advanced-stage MMel treated at high-volume facilities had significantly improved survival and were more likely to receive chemotherapy and immunotherapy.

AB - Background: The advent of targeted therapies and immunomodulatory agents has revolutionized the management of advanced cutaneous malignant melanoma (MMel) by prolonging overall survival. This study evaluated the therapeutic and survival disparities among patients with advanced MMel based on hospital volume using the National Cancer Database (NCDB). Methods: A retrospective analysis using regression models and Kaplan-Meier estimates was performed from the data obtained from the NCDB on patients with MMel diagnosed in 2004 through 2015. Results: A total of 40,676 patients with MMel were treated at 1,260 facilities. Multivariable analysis showed that facility volume was an independent predictor of overall survival (P,.0001). Compared with patients treated at high-volume facilities (tertile 3 [T3]), those with stage III disease (n527,528) treated at intermediate-and low-volume facilities (T2 and T1, respectively) had a significantly higher risk of death (T2 hazard ratio [HR], 1.15; 95% CI, 1.09-1.20; T1 HR, 1.23; 95% CI, 1.17-1.29). Compared with patients treated at T3 facilities, those with stage IV disease (n513,148) treated at lower-tertile facilities had a significantly higher risk of death (T2 HR, 1.16; 95% CI, 1.10-1.21; T1 HR, 1.29; 95% CI, 1.23-1.36). Further, patients with stage IV disease treated at T3 facilities (vs T1 facilities) were more likely to receive chemotherapy (38% vs 28%) and immunotherapy (23% vs 10%) (P,.0001). Conclusions: Patients with advanced-stage MMel treated at high-volume facilities had significantly improved survival and were more likely to receive chemotherapy and immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85074623764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074623764&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.7320

DO - 10.6004/jnccn.2019.7320

M3 - Article

C2 - 31693989

AN - SCOPUS:85074623764

VL - 17

SP - 1334

EP - 1342

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 11

ER -